EyePoint Pharmaceuticals Inc. (EYPT)’s Financial Results Comparing With Aeglea BioTherapeutics Inc. (NASDAQ:AGLE)

Both EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) and Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
EyePoint Pharmaceuticals Inc. 6.94M 23.39 101.70M -1.37 0.00
Aeglea BioTherapeutics Inc. 2.38M 74.97 53.40M -2.21 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of EyePoint Pharmaceuticals Inc. and Aeglea BioTherapeutics Inc.

Profitability

Table 2 provides us the return on equity, net margins and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
EyePoint Pharmaceuticals Inc. -1,465.42% -305.3% -111.2%
Aeglea BioTherapeutics Inc. -2,243.70% -66.6% -59.8%

Liquidity

The Current Ratio and Quick Ratio of EyePoint Pharmaceuticals Inc. are 2.2 and 2.2 respectively. Its competitor Aeglea BioTherapeutics Inc.’s Current Ratio is 10.7 and its Quick Ratio is 10.7. Aeglea BioTherapeutics Inc. can pay off short and long-term obligations better than EyePoint Pharmaceuticals Inc.

Analyst Ratings

The Ratings and Recommendations for EyePoint Pharmaceuticals Inc. and Aeglea BioTherapeutics Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
EyePoint Pharmaceuticals Inc. 0 0 0 0.00
Aeglea BioTherapeutics Inc. 0 0 1 3.00

Meanwhile, Aeglea BioTherapeutics Inc.’s consensus price target is $14, while its potential upside is 126.54%.

Institutional and Insider Ownership

Roughly 55.9% of EyePoint Pharmaceuticals Inc. shares are owned by institutional investors while 67.4% of Aeglea BioTherapeutics Inc. are owned by institutional investors. EyePoint Pharmaceuticals Inc.’s share owned by insiders are 0.7%. Insiders Competitively, owned 1% of Aeglea BioTherapeutics Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
EyePoint Pharmaceuticals Inc. 12.96% 9.58% -32.22% -20.43% -6.15% -3.17%
Aeglea BioTherapeutics Inc. -0.58% -5.79% -13.54% -24.95% -33.5% -8.81%

For the past year EyePoint Pharmaceuticals Inc.’s stock price has smaller decline than Aeglea BioTherapeutics Inc.

Summary

Aeglea BioTherapeutics Inc. beats on 6 of the 11 factors EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. Its human enzymes are designed to degrade specific amino acids in the blood. The companyÂ’s lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies. Its pipeline of engineered human enzyme product candidates in preclinical development includes AEB3103, an enzyme that degrades the amino acids cysteine to target cancer to oxidative stress; AEB2109, an enzyme that degrades the amino acid methionine to target methionine dependent cancers; and AEB4104, an engineered human enzyme to treat another inborn errors of metabolism by degrading the amino acid homocysteine. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea Biotherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.